---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000072"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:13.903530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026

## Summary
- Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.
- Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.
- Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.
- ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.
- ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients.

## SEC filing metadata
- accession: 0001737287-24-000072
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/0001737287-24-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/allo-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000072
- JSON: https://secwatch.observer/filing/0001737287-24-000072.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.